atai life sciences market cap

ATAI Life Sciences Revenues. Find the latest ATAI Life Sciences N.V. (ATAI) stock quote, history, news and other vital information to help you with your stock trading and investing. Source: Nasdaq Atai… atai Life Sciences, the psychedelic medicine industry’s market cap leader, has just announced the launch of its new philanthropic program, atai Impact. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. ATAI Life Sciences NV (ATAI) stock price, charts, trades & the US's most popular discussion forums. ATAI Life Sciences: A Look at Q2 Results and Highlights. Atai was already a major early investor in Compass, and this move increases its ownership from 19.4% to 20.8%. ATAI Life Sciences sets IPO terms, to be valued at up to $2.3 billion. Description. Market Cap: 1,813M Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. And over the seven months that followed, those shares would have rocketed up to a peak gain of 21,433%! Atai Life Sciences, the psychedelic medicine industry’s leader by market cap, has announced the purchase of another 619,095 Compass Pathways shares. Atai has bought another 420,000 shares in Compass Pathways in recent days, raising its stake in the company from 19.4% to 20.8%. Actively observing the price movement in the last trading, the stock closed the session at … ATAI Stock Price Today. Blackstone announced its proposed strategic investment in Life Science Logistics. Today ATAI stock price opened at $16.93 after previous close of $16.60. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ATAI Stock Price Today. ATAI Life Sciences N.V. Analyst Report: NetEase, Inc.NetEase, which started on an Internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming] After its initial day of trading, atai Life Sciences sits with a market cap of ~$3 billion. ATAI holds a significant percentage of Compass (22%), but Compass is only one R&D platform among ATAI’s big tent of psychedelic drug R&D partnerships. Atai Life Sciences (ATAI) Atai Life Sciences is a biopharmaceutical company that aims to incubate development of treatments for people with mental health disorders. Market Cap. Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. Latham & Watkins stands out in complex cross-border equity capital markets transactions, with its London team active in big-ticket listings and other equity fundraises in Europe and further afield internationally. Set up two years ago, it has attracted more than US$100mln in Series A and B funding that has brought in an impressive roster of early investors, including Peter Thiel, the co-founder of both PayPal and Palantir GK focuses on multiple investment themes with potential widespread impact to create a growth-focused portfolio of large, mid and small cap stocks. Atai Life Sciences, the psychedelic medicine industry’s leader by market cap, has announced the purchase of another 619,095 Compass Pathways shares. However, some observers (including Psychedelic Stock Watch) see that as a very conservative range. 1.36B. ATAI stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Woodline Partners LP, Citadel Advisors LLC, Price T Rowe Associates Inc. MD, Millennium Management LLC, Healthcare of Ontario Pension Plan Trust Fund, and Brown University. ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. In July of 2016, this micro-cap was trading for just 1.5 cents a share. Dividend (Yield) 23.74 (2 ... ATAI Life Sciences BV. Apeiron completes deals across the entire lifecycle and balance sheet of a company, […] 4. For example, plant based food market is expected to explode 100 … $19.88 mil (last 12 months) Net Income. At its high ($47.30 per share), it had a market cap in excess of $1.6 billion. Get ATAI Life Sciences NV (ATAI:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX … News ATAI Life Sciences N.V.ATAI. View ATAI financial statements in full. It has a current market cap of $1.2 billion. It is based in the United Kingdom. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. Last week atai Life Sciences reported its financial results and business update for this year’s second quarter. The AdvisorShares Psychedelics ETF (NYSE ticker: PSIL) invests in the emerging psychedelic drugs sector, offering exposure to those biotechnology, pharmaceutical and life sciences companies we see as leading the way in this nascent industry. Atai Life Sciences (NASDAQ:ATAI) $2.7 billion. atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the third quarter ended September 30, 2021, and provided its corporate update. Join Captain Solutions for stock market insights, trends and analysis from the best investors and traders on twitter. 1.79B. atai Life Sciences (NASDAQ:ATAI) added ~5.6% in the pre-market after the German pharma company focused on psychedelics for mental disorders attracted two new buy ratings. 09/11/2021 10:29:39 1-888-992-3836 Free Membership Login View detailed financial information, real-time news, videos, quotes and analysis on ATAI Life Sciences N.V. (NASDAQ:ATAI). MYND was founded by Dr. Wilfred Jefferies and Dr. Lyle Oberg, with Dr. Jefferies being a renowned neuroimmunologist with over 60 patents and 100 journal publications. ATAI Life Sciences N.V key financial stats and ratios If you want to check out ATAI market capitalization, P/E Ratio, EPS, ROI, and other financial ratios, this page is your go-to hub. It’s currently trading at $30.66 as of August 22, down 16.55% in the past month, with a market cap of $1.28 billion. Here’s Our Rant About Atai Life Sciences N.V. (ATAI) newsheater 11/16/2021. Atai Life Sciences has received 65.95% “outperform” votes from our community. The firm has a market cap of over $100 million and a 279% return on equity. It will be just as important for Compass to succeed over the coming months as it will for ATAI’s portfolio companies to perform. Meanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. Stock Chart. The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range. Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of ... The public information regarding Atai Life Sciences's current market price is not available at this time. TradingView Medium Chart Widget. Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the … Market Cap (MIL) 1,914.75: Forward P/E-15.17: Dividend (Yield %)--Advanced Charting. Mynaric (Nasdaq:MYNA) soared following a U.S. IPO for the German laser firm, which is backed by mega-investor Christian Angermayer of hallucinogens company … Market Cap 6.68 B. Community Sentiment. Atai Life Sciences has received 159 “underperform” votes. An overview of all the stock ticker symbols listed. ATAI Life Sciences NV stock was originally listed at a price of $19.45 in Jun 18, 2021. Cash and cash equivalents totaled $430.3M as of September 30, 2021, compared to … ATAI has a market cap or net worth of $1.79 billion. ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. The company’s shares closed last Monday at $12.58, close to its 52-week low of $12.35. The enterprise value is $1.36 billion. Atai Life Sciences, the psychedelic medicine industry’s leader by market cap, has announced the purchase of another 619,095 Compass Pathways shares. atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression. $-153.54 mil (last 12 months) IPO Profile. $2126.04mil. ATAI Life Sciences B.V.*. Atai Life Sciences, the psychedelic medicine industry’s leader by market cap, has announced the purchase of another 619,095 Compass Pathways shares. 11, 2021 at 1:53 p.m. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Primary metrics and data points about Atai Life Sciences N.V.. Market Cap: $2B. 2 min read. Atai Life Sciences listed on Nasdaq for its IPO on June 18, 2021.Source: NasdaqAtai Life Sciences, the Peter Thiel-supported start-up that aims to use psychedelic drugs to treat mental illness, has increased its stake in the drug developer Compass Pathways.Atai bought an additional 420,000 Compass Pathways shares in Atai Life Sciences (ATAI) Atai Life Sciences is a biopharmaceutical company that aims to incubate development of treatments for people with mental health disorders. Would investors rather have a piece of atai, or a much bigger piece of all these other companies? At Insider Monkey, we scour multiple sources to uncover the next great investment idea. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Key Data Points. At Compass’ current market cap of ~$1.1 billion, ATAI has a $200 – 300 million stake in the company. Explore commentary on … … Find the latest ATAI LIFE SCIENCES BV EO1 (9VC.BE) stock quote, history, news and other vital information to help you with your stock trading and investing. ATAI Life Sciences has 35 employees at their 1 location. 52wk Range: Description. Jun. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The combined market cap of Cybin, Field Trip and all these other smaller players is less than one-third that of atai. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The combined market cap of Cybin, Field Trip and all these other smaller players is less than one-third that of atai. No news for in the past two years. It should instantly compete for market cap supremacy with COMPASS Pathways upon its listing and could sustain a leadership position—at least until COMPASS reports Phase 2B endpoint results late this year (providing they are stellar). It’s currently trading at $30.66 as of August 22, down 16.55% in the past month, with a market cap of $1.28 billion. The top five public psychedelics companies by market cap — Atai Life Sciences, Compass Pathways, GH Research, MindMed, and Cybin … ATAI Life Sciences N.V. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a … The purported "big dawg" is coming to town and might make a … James Inness and Chris Horton co-head the practice, which is notably strong in the technology sector. 160.30 M … “Following our IPO in June, we continue to see positive momentum. June 14, 2021 Mukund Mohan. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. Market Cap. In recent days, Atai Life Sciences (Compass’ biggest shareholder) increased its ownership in Compass Pathways buying another 619,095 … Revenues. During the day, Atai Life Sciences stock quote has varied from a low of $15.87 to a high of $17.00. With ATAI Life Sciences NV stock trading at $13.99 per share, the total value of ATAI Life Sciences NV stock (market capitalization) is $2.17B. ATAI Life Sciences NV (ATAI): Price Up $0.18 (1.05)% Over Past Day, Down $-0.05 (-0.31)% Over Past Hour ETF Daily News 2021-11-08 Market Cap. Atai Life Sciences, the Peter Thiel-backed startup that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in drug development company Compass Pathways. NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to … Financial summary of ATAI Life Sciences N.V with all the key numbers. CSE: MYND. Apeiron completes deals across the entire lifecycle and balance sheet of a company, […] Atai was already a major early investor in Compass, and this move increases its ownership from 19.4% to 20.8%. Atai Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. If atai trades in the expected manner off its IPO, it will quickly have a market cap greater than the combined market caps of every other psychedelic drug public company today Investors in psychedelic stocks will be aware that atai Life Sciences just raised another big whack of cash. Explore the stock pages to learn about the company’s price history, financials, key stats, and more. atai Life Sciences Reports Second Quarter 2021 … ATAI Life Sciences NV (ATAI): Price Up $0.18 (1.05)% Over Past Day, Down $-0.05 (-0.31)% Over Past Hour ETF Daily News 2021-11-08 atai Life Sciences B.V. is based in BERLIN. Provide the latest ATAI Life Sciences NV(ATAI) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade ATAI Life Sciences NV stocks，we will provide investors with reference decision data. Market Cap Revenue; Medical: Medical - Outpatient & Home Care: $1.739B: $0.000B: atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. You can buy and sell ATAI Life Sciences (ATAI) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. As of the previous market close, atai Life Sciences N.V. has a market cap of $2.62B, which represents its share price of $17.18 multiplied by its outstanding shares number of 152.57M. Atai Life Sciences N.V. (NASDAQ:ATAI) Achieved Almost 15.03% Growth In A Month. The current ATAI market cap is 2.585B. $-153.54 mil (last 12 months) IPO Profile. Atai Life Sciences at the Nasdaq for its IPO, June 18, 2021. German Psychedelics startup $ATAI backed by Peter Thiel, Atai life sciences, an early stage mental health drug development companies is going public at $2.3B market cap, raising $215M. In depth view into ATAI Life Sciences Market Cap including historical data from 2021, charts, stats and industry comps. 1.36B. ... Market Cap. Latest Developments More. The stock opened with a gain of 0.00% at $12.20 and touched an intraday high of $12.26, rising 0.49% against the last close of $12.20. 9VC | Complete ATAI Life Sciences N.V. stock news by MarketWatch. MYND Life Sciences is a biotech firm focused on developing psychedelic medicines based on neuro-anti-inflammatory substances. Atai Life Sciences employs 35 workers across the globe. Atai Life Sciences at the Nasdaq for its IPO, June 18, 2021. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The largest stake in Atai Life Sciences N.V. (NASDAQ:ATAI) was held by Falcon Edge Capital, which reported holding $48.6 million worth of stock at … Blackstone is making the investment through funds managed by […] November 27, 2021 Bain Capital Private Equity’s Majority Investment in InnovaCare Health. ATAI: Get the latest ATAI Life Sciences stock price and detailed information including ATAI news, historical charts and realtime prices. Atai Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.06% to the previous day’s close as strong demand from buyers drove the stock to $11.19. $ATAI I thought I’d take a Q&A approach to this company since there are no revenues, no earnings or metrics to speak of immediate term. Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. See insights on ATAI Life Sciences including office locations, competitors, revenue, financials, executives, subsidiaries and … ATAI Life Sciences NV (ATAI) share price, charts, trades & the UK's most popular discussion forums. After its initial day of trading, atai Life Sciences sits with a market cap of ~$3 billion. If you had invested in ATAI Life Sciences NV stock at $19.45, your return over the last 0 years would have been -28.07% (not including any dividends or dividend reinvestments). Financial Information. Day's Range: $10.87 - $11.54. About ATAI. Total Valuation. The goal of the AdvisorShares Gerber Kawasaki ETF (GK) is to identify growth companies positioned to benefit from transformative changes in our society. ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment … Find the latest ATAI Life Sciences N.V. (ATAI) stock quote, history, news and other vital information to help you with your stock trading and investing. Enterprise Value. $19.88 mil (last 12 months) Net Income. Being the industry’s perennial powerhouse and current market cap leader, a deeper look at the results might be a good idea. Atai Life Sciences has a market capitalization of $1.79 billion. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. Market Cap. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. We would like to show you a description here but the site won’t allow us. Atai Life Sciences, which supports psychedelic drug developers seeking new ways to treat mental illness, hopes to raise $100 million in an initial public offering. Meanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. ATAI Life Sciences NV has a market cap of $2059690950. info@atai.life We show 5 historical shares outstanding datapoints in our ATAI shares outstanding history coverage, used to compute ATAI market cap on those dates. Market cap measures what a company is worth on the open market, as well as the market’s perception of its prospects because it reflects what investors are willing to pay for its stock. $2126.04mil. ATAI has a market cap or net worth of $1.79 billion. ATAI Life Sciences (NASDAQ: ATAI): Q3 GAAP EPS of -$0.21 beats by $0.02. Atai Life Sciences listed on Nasdaq for its IPO on June 18, 2021.Source: NasdaqAtai Life Sciences, the Peter Thiel-supported start-up that aims to use psychedelic drugs to treat mental illness, has increased its stake in the drug developer Compass Pathways.Atai bought an additional 420,000 Compass Pathways shares in Financial Information. Does ATAI Life Sciences' 'biotech platform' provide the antidote to traditional drug discovery model? 1,239 Followers, 304 Following, 12 Posts - See Instagram photos and videos from abdou now online (@abdoualittlebit) Total Valuation. ATAI Life Sciences N.V. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Current market speculation is that ATAI will be valued between $1 - $2 billion when it commences public trading. The current stock price of Atai Life Sciences is $15.93. On average, they expect ATA's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price. View analysts' price targets for ATA or view top-rated stocks among Wall Street analysts. Stock analysis is a method for investors and traders to make buying and selling decisions. Comparatively, 7.6% of Atai Life Sciences shares are held by institutional investors. Peter Thiel’s Atai Life Sciences and 5 Other Companies List Shares Jun. Source: Nasdaq Atai… atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update. info@atai.life We show 5 historical shares outstanding datapoints in our ATAI shares outstanding history coverage, used to compute ATAI market cap on those dates. 52.9% of Atai Life Sciences shares are held by insiders. ... ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. ATAI Life Sciences B.V.*. Would investors rather have a piece of atai, or a much bigger piece of all these other companies? Free forex prices, toplists, indices and lots more. Atai Life Sciences N.V. (ATAI) stock plummeted over -7.70% intraday to trade at $11.26 a share on NASDAQ. Get ATAI Life Sciences NV (9VC-FF:Frankfurt Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. ; Initiating the … It employs 35 people.. The psychedelic sector will soon have a “Big 3”, and atai Life Sciences will be among its crown jewels. No data provided. Next ATAI Life Sciences N.V earnings date is November 16, the estimation is 0.00. Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, his family office and merchant banking business. About ATAI Life Sciences NV: ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Etihad Airways Covid Test For Child, Soccer Player Needing Cpr, Who Was With River Phoenix When He Died, Libra Daily Horoscope, Michael Jordan Wizards Jersey, Karate Kid 3 Rotten Tomatoes, Invisible Payments Definition, Where Did Arthur Conan Doyle Live,